Cancer Center Amsterdam

Consensus Statement on Mandatory Measurements for Pancreatic Cancer Trials for Patients with Resectable or Borderline Resectable Disease (COMM-PACT-RB): A Systematic Review and Delphi Consensus Statement

Pijnappel, E. N., Suurmeijer, J. A., Koerkamp, B. G., Kos, M., Siveke, J. T., Salvia, R., Ghaneh, P., van Eijck, C. H. J., van Etten-Jamaludin, F. S., Abrams, R., Brasiūnienė, B., Büchler, M. W., Casadei, R., van Laethem, J-L., Berlin, J., Boku, N., Conroy, T., Golcher, H., Sinn, M., Neoptolemos, J. P., & 4 othersvan Tienhoven, G., Besselink, M. G., Wilmink, J. W. & van Laarhoven, H. W. M., Jun 2022, In: JAMA oncology. 8, 6, p. 929-937 9 p.

Research output: Contribution to journal › Review article › Academic › peer-review

The fear of cancer recurrence and progression in patients with pancreatic cancer

Dutch Pancreatic Cancer Group, Jun 2022, In: Supportive Care in Cancer. 30, 6, p. 4879-4887 9 p.

Research output: Contribution to journal › Article › Academic › peer-review

First- and Second-Line Palliative Systemic Treatment Outcomes in a Real-World Metastatic Pancreatic Cancer Cohort

Dutch Pancreatic Cancer Group, 1 May 2022, In: Journal of the National Comprehensive Cancer Network. 20, 5, p. 443-450 8 p.

Research output: Contribution to journal › Article › Academic › peer-review